- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06768489
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
-
Clayton, Australië, 3168
- Werving
- Monash Medical Centre
-
Fitzroy, Australië, 3065
- Werving
- St Vincents Hospital Melbourne
-
Melbourne, Australië, 3000
- Werving
- Peter MacCallum Cancer Centre
-
Waratah, Australië, 2298
- Werving
- Calvary Mater Newcastle Hospital
-
Wollongong, Australië, 2500
- Werving
- Wollongong Hospital
-
-
-
-
-
Haifa, Israël, 3436212
- Werving
- Carmel Medical Center
-
Jerusalem, Israël, 9112001
- Werving
- Hadassah Medical Center
-
Ramat Gan, Israël, 52621
- Werving
- Sheba Medical Center
-
Tel Aviv, Israël, 64239
- Werving
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Werving
- VU Medisch Centrum
-
Groningen, Nederland, 9713 GZ
- Werving
- Universitair Medisch Centrum Groningen
-
Utrecht, Nederland, 3584 CX
- Werving
- UMC Utrecht
-
-
-
-
-
Barcelona, Spanje, 08036
- Werving
- Hosp. Clinic de Barcelona
-
Salamanca, Spanje, 37007
- Werving
- Hosp Clinico Univ de Salamanca
-
-
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Colorado Blood Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Winship Cancer Institute Emory University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (R/R MM):
- Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
- Meet treatment regimen-specific requirements as follows: Treatment regimen A (JNJ-79635322+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (JNJ-79635322+pomalidomide): Have received greater than or equal to (>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR >=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, and E: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments
- Have a weight >=40 kilograms
- Must have an Eastern Cooperative Oncology Group status of 0 or 2
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level >= 0.5 gram per deciliter (g/dL); or b) Urine M-protein level >=200 milligram (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated
Inclusion criteria for newly diagnosed amyloid light chain (ND AL) Amyloidosis
- Have a histopathological diagnosis of amyloidosis
- Have an ECOG performance status of 0 to 1
Inclusion criteria for High-risk smoldering multiple myeloma (SMM)
- Have a diagnosis of SMM (per IMWG criteria) for less than or equal to (<=) 5 years with measurable disease at the time of enrollment as defined in the protocol
- Have an ECOG performance status of 0 to 1
Exclusion Criteria for NDMM and R/R MM:
- Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days
- Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant <=12 weeks before the first dose of study treatment
- Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy grade <=3)
- Prior treatment with CD3-redirecting therapy
Exclusion Criteria for ND AL Amyloidosis
- Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60 percent (%) plasma cells in the bone marrow, or hypercalcemia
- Macroglossia that impairs swallowing difficulty
- Prior therapy for AL amyloidosis or multiple myeloma
Exclusion Criteria for High-risk SMM
- Multiple myeloma, requiring treatment
- Primary systemic AL (immunoglobulin light chain) amyloidosis
Exclusion criteria for all participants:
- Any serious underlying medical conditions, such as: Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment; active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment; cardiovascular dysfunction; pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation; human immunodeficiency (HIV) infection; active hepatitis B or C infection; stroke or seizure within 6 months prior to first dose of study treatment
- Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than (<) 50 percent (%)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment Regimen A and C: JNJ-79635322+Daratumumab
Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive JNJ-79635322 along with daratumumab to establish the recommended phase 2 doses (RP2D[s]) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. JNJ-79635322 will be administered subcutaneously. |
|
Experimenteel: Treatment Regimen B: JNJ-79635322+Pomalidomide
Participants who have received greater than or equal to (>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or >=2 prior lines of therapy, including a PI and lenalidomide will receive JNJ-79635322 along with pomalidomide to establish the RP2D(s) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Pomalidomide will be administered orally. JNJ-79635322 will be administered subcutaneously. |
|
Experimenteel: Treatment Regimen D and E: JNJ-79635322 + Daratumumab + Lenalidomide Combination
Participants with NDMM will receive JNJ-79635322 along with daratumumab and lenalidomide to establish the RP2D[s] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Lenalidomide will be administered orally. Daratumumab will be administered subcutaneously. JNJ-79635322 will be administered subcutaneously. |
|
Experimenteel: Treatment Regimen F: JNJ-79635322 + Daratumumab
Participants with newly diagnosed amyloid light chain (ND AL) amyloidosis will receive JNJ-79635322 in treatment regimen F along with daratumumab to establish the RP2D[s] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. JNJ-79635322 will be administered subcutaneously. |
|
Experimenteel: Treatment Regimen G: JNJ-79635322 + Daratumumab
Participants with high-risk smoldering multiple myeloma (SMM) will receive JNJ-79635322 in treatment regimen G along with daratumumab to establish the RP2D[s] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens. |
Daratumumab will be administered subcutaneously. JNJ-79635322 will be administered subcutaneously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
Tijdsspanne: Up to 28 days
|
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 28 days
|
|
Number of Participants with Adverse Events (AEs) by Severity
Tijdsspanne: Up to 3 Years and 3 months
|
An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event. |
Up to 3 Years and 3 months
|
|
Number of Participants with Clinically Significant Laboratory Abnormalities
Tijdsspanne: Up to 3 Years and 3 months
|
Participants with clinically significant laboratory abnormalities (hematology and chemistry) will be reported. |
Up to 3 Years and 3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants With Overall Response Rate
Tijdsspanne: Up to 3 Years and 3 months
|
Overall response rate is defined as percentage of participants with newly diagnosed multiple myeloma (NDMM), relapsed or refractory multiple myeloma (R/R MM), or high-risk smoldering multiple myeloma (SMM) who have a partial response (PR) or better evaluated by the investigator as per international myeloma working group (IMWG) 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response Rate
Tijdsspanne: Up to 3 Years and 3 months
|
VGPR or better response rate is defined as the percentage of participants with NDMM, R/R MM, or high-risk SMM who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With CR or Better Response Rate
Tijdsspanne: Up to 3 Years and 3 months
|
CR or better response rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With sCR or Better Response Rate
Tijdsspanne: Up to 3 Years and 3 months
|
sCR rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve an sCR according to the IMWG 2016 criteria. |
Up to 3 Years and 3 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per IMWG 2016 response criteria, or death due to progression, whichever occurs first in participants with NDMM, R/R MM, or high-risk SMM. |
Up to 3 Years and 3 months
|
|
Time to Response (TTR)
Tijdsspanne: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participants with NDMM, R/R MM, or high-risk SMM has met all criteria for PR or better as defined by IMWG 2016 response criteria. |
Up to 3 Years and 3 months
|
|
Percentage of Participants With Hematologic Response As Defined by International Amyloidosis Consensus Criteria
Tijdsspanne: Up to 3 Years and 3 months
|
Hematologic response is defined as percentage of participants with newly diagnosed amyloid light chain (ND AL) amyloidosis who achieve complete response, very good partial response, partial response, no response and progression as defined by International amyloidosis consensus criteria present in the protocol will be reported. |
Up to 3 Years and 3 months
|
|
DOR as Defined by International Amyloidosis Consensus Criteria
Tijdsspanne: Up to 3 Years and 3 months
|
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per International amyloidosis consensus criteria, or death due to progression, whichever occurs first in participants with ND AL amyloidosis. |
Up to 3 Years and 3 months
|
|
TTR as Defined by International Amyloidosis Consensus Criteria
Tijdsspanne: Up to 3 Years and 3 months
|
TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant with ND AL amyloidosis has met all criteria for PR or better as defined by International amyloidosis consensus criteria. |
Up to 3 Years and 3 months
|
|
Serum Concentration of JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
Serum samples will be analyzed to determine concentrations of JNJ-79635322 and daratumumab. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUCinf) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
AUCinf for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve from Time Zero to the Last Measurable Concentration [AUC(0-t)] for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
AUC(0-t) for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Area Under the Serum Concentration Time Curve During the Dosing Interval (AUCtau) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
AUCtau for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Maximum Serum Concentration (Cmax) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
Cmax for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Half Life (T1/2) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
T1/2 for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Time to Reach Cmax (Tmax) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
Tmax for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Systemic Clearance (CL/F) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
CL/F for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Apparent Volume of Distribution at Steady State (Vss/F) for JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
Vss/F for JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies to JNJ-79635322 and Daratumumab
Tijdsspanne: Up to 3 Years and 3 months
|
Participants with anti-drug antibodies to JNJ-79635322 and daratumumab will be reported. |
Up to 3 Years and 3 months
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata
- Metabole ziekten
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Voorstadia van kanker
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Proteostase-tekortkomingen
- Hypergammaglobulinemie
- Amyloïdose
- Voedings- en stofwisselingsziekten
- Hemische en lymfatische ziekten
- Immunoglobuline lichte keten amyloïdose
- Smeulend multipel myeloom
- Multipel myeloom
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Carbonzuren
- Piperidines
- Phtalimiden
- Phtaliczuren
- Zuren, carbocyclisch
- Piperidones
- Isoindoles
- Lenalidomide
- pomalidomide
- daratumumab
Andere studie-ID-nummers
- 79635322MMY1002
- 2024-515316-44-00 (Register-ID: EUCT number)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .